Thursday, July 14, 2016

BRIEF-Revance Therapeutics plans to initiate global phase 3 program in second half of 2016

* Revance Announces Completion Of Pre-Phase 3 meeting with

FDA for rt002 injectable to treat glabellar lines

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)